

Shingrix In Recipients of Allogeneic Transplants

NCT05775718

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Colorado, Denver
Enrollment	55 participants

Key Eligibility Criteria

Inclusion (9)

- Allo-SCT recipients being age 18 - 79 years at time of allo-SCT.
- Written informed consent being obtained from the subject
- Two doses of RZV, separated by 2 to 6 months, administered at least 1 year after allo-SCT.
- Enrollment at \geq 18 months after second dose of Shingrix.
- Female subjects of childbearing potential (FOCBP) enrolled in the study only if they:
... and 4 more (see full listing online)

Exclusion (8)

- Active Graft Versus Host Disease (aGVHD) at the time of enrollment and receipt of the third dose of RZV
- Having received \geq 20 mg prednisone for more than 2 weeks (or equivalent) in the 8 weeks preceding enrollment.
- Receiving any significant immunosuppressive therapy other than for graft maintenance, in the opinion of the investigator.
- Having received a live attenuated vaccine within the last 4 weeks, or inactivated vaccine in the last 2 weeks, prior to enrollment.
- Having a history of HZ after the administration of the primary 2-dose RZV immunization regimen.
... and 3 more (see full listing online)

Locations (1 total)

University of Colorado Hospital, Aurora, Colorado, United States